Search
Imelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigationalImelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCertain SARS-CoV-2 Omicron subvariants may be associated with resistance to monoclonal antibodies, such as EVUSHELD. … [A243351, A243356, L39411] As the RBD binding site of cilgavimab does not overlap with that of [tixagevimab], the two can be administered to synergistically impair SARS-CoV-2 infection in individuals who
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalCertain SARS-CoV-2 Omicron subvariants may be associated with resistance to monoclonal antibodies, such as EVUSHELD. … [A243351, A243356, L39411] As the RBD binding site of tixagevimab does not overlap with that of [cilgavimab], the two can be administered to synergistically impair SARS-CoV-2 infection in individuals who
Oxygen
go.drugbank.com/drugs/DB09140ApprovedInvestigationalVet approvedOxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen...
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Technetium Tc-99m oxidronate
go.drugbank.com/drugs/DB09139ApprovedWithdrawnTechnetium Tc-99m oxidronate, also known as 99mTc-methylene diphosphonate, is a radiopharmaceutical agent. … A radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy.
Pregabalin
go.drugbank.com/drugs/DB00230ApprovedInvestigational[A187190] Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalTPOR is a regulatory target site for endogenous thrombopoietin, which acts as a primary cytokine to promote megakaryocyte proliferation and differentiation, and affect other hematopoietic lineages as well
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
Methyltestosterone
go.drugbank.com/drugs/DB06710ApprovedInvestigationalMethyltestosterone is a schedule III drug in the US.